about
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecanTRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trialsInitial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerProspective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabBeyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancerClinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.First-line chemotherapy for mCRC—a review and evidence-based algorithm.TAS-102 for the treatment of metastatic colorectal cancer.An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer.Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy.Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer.Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy.Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM).TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancerClinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancerFOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerImmunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
P50
Q28274019-5F2FDE49-0E0F-4CA9-8F3A-97E8514FBD68Q30855372-2BB541C8-D8A6-4A80-B0BA-94D9D3699EABQ33933669-7B75DA6D-C87B-4B23-8E29-F26BE1EC7CCCQ34444495-3E3A04D1-2517-4451-A322-556CC35101E9Q34625531-9FA01BA2-5FC8-46F1-8A38-DC0580A6B658Q34806780-C34AE6CD-7BF6-4194-BFE3-E479A8631020Q34825323-46647FE1-037C-4BA2-AE7D-530C7E6D6F6FQ35076220-93C2E612-3E57-4CCD-9110-4AD0F68E7561Q36472959-2EC07F17-3625-4800-B7C9-0705E7E55C34Q36545358-BAF2F1C2-F5F6-4C18-8DD3-1E01EE91A859Q36841039-ACFDF7EA-3E5F-4E0C-88B0-BB04DC6656D4Q36959113-FBB81F87-CA56-4C38-802E-25B7EE44E278Q37330719-EE971512-2132-4FE4-BC0E-56C1C349F361Q38555200-C41738EF-8A4B-458A-9255-CD8D13ACD38EQ38618169-E64146C2-FD26-4FDC-B001-62FCF086C48AQ38857704-442C1396-C648-462C-AB30-2FC9D884BD97Q39011428-1CD311E3-0FFA-4752-892D-AD045FFD654FQ41562027-B7F9324D-3B0E-4EC9-BF6A-905FC534207DQ41835603-92F3B875-E091-4E19-8242-E570C9113860Q43125608-96B2AD2A-EB3D-4E04-8890-798C113FAF66Q43253760-4031377B-7D0F-48A0-A097-B2B038A83DDEQ43925665-6CF54E3D-1C89-4656-8E65-43C5A6E5C236Q43991765-DFE8271E-811C-446D-86FA-0F0E163AED4FQ44995693-1460DDC2-FBE1-4411-9293-BE027EC5CC98Q46099008-250CD961-5D85-4C35-A968-3E054E2FC41AQ46201420-E967E014-633F-4F61-A47E-B2DA2D75D6F5Q46253386-BD6A4254-6C5F-420C-9DB2-5068D0BEEBB8Q46301372-22545A61-9F33-4BAE-BAB0-D1C3557D875DQ46852357-7B81C4BE-CDF5-46E5-B5E4-72D84108987AQ48523391-6C568A22-9A78-4101-AE28-4EEA5AB928FEQ49951874-12C794F6-F9AD-468D-9093-C788883B45A3Q50862095-E1CA9E1B-6D9C-450E-AA54-1F5EB60E8502Q51195465-8CE6F4A2-CCFC-4B89-923E-781C894B86ACQ52595509-53D76AAD-5E40-4EE8-AA39-92925B71F6C5Q52629448-E29E6FB7-1109-48C9-A53D-BD26798A4287Q55032398-B722AB27-E9FE-4B8C-AC6E-1AAA9D295954Q56368555-F547676E-CBEE-4CA4-9717-89101BA4E7D4Q57424151-881E4C0E-920A-4CB9-9DCB-297698FB4271Q59218920-65D84909-75EC-4E2D-9A6A-51BE164990C8Q60169780-5E8737DC-64C9-44F5-B15D-71B373F21D4F
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Lisa Salvatore
@en
Lisa Salvatore
@nl
type
label
Lisa Salvatore
@en
Lisa Salvatore
@nl
prefLabel
Lisa Salvatore
@en
Lisa Salvatore
@nl
P31
P496
0000-0003-3864-0719